CRYOPORT, INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
CRYOPORT, INC. (CYRX) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $98.10 thousand for the 12-month period ending 2016-03-31, per its 10-KT filed 2017-03-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2017-03-13
- CRYOPORT, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2016-03-31 was $0.00.
- CRYOPORT, INC. research and development asset acquired other than through business combination, written-off for fiscal 2016 was $98.10K.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|
| 2016-03-31 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2017-03-13 | $98.10K 10-KT · filed 2017-03-13 | |
| 2015-12-31 | $98.10K 10-Q · filed 2016-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |